Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PARK7 pseudogene 2 (PARK7P2) is a non-protein-coding genomic sequence annotated as a pseudogene of PARK7 (DJ-1), which means it does not produce a functional protein. There is no evidence supporting a role for PARK7P2 in cellular function, disease, or therapeutic intervention. By contrast, the PARK7 (DJ-1) gene encodes a protein involved in oxidative stress response, neuroprotection, protein folding, and is genetically associated with hereditary forms of Parkinson's disease[3][2][1]. PARK7P2 is not referenced in the biomedical literature as a target for drug discovery or as relevant to disease biology, suggesting that it is not a molecular target of current scientific or clinical interest. If you seek information about PARK7 (DJ-1)—a canonical target implicated in neurodegenerative disorders—I can provide those details. For PARK7P2, current evidence suggests it is not a therapeutic, diagnostic, or biological target.
None (not a functional molecule for drug mechanism)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PARK7 pseudogene 2 (PARK7P2).